nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—P-Glycoprotein Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.34	0.521	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.312	0.479	CiPCiCtD
Everolimus—FKBP1A—Cyclosporine—focal segmental glomerulosclerosis	0.275	0.972	CbGbCtD
Everolimus—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.00779	0.0276	CbGbCtD
Everolimus—Graft loss—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.069	CcSEcCtD
Everolimus—Uraemic syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.069	CcSEcCtD
Everolimus—Gingival hypertrophy—Cyclosporine—focal segmental glomerulosclerosis	0.00339	0.0596	CcSEcCtD
Everolimus—Thrombotic microangiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.0396	CcSEcCtD
Everolimus—Lymphoproliferative disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.0367	CcSEcCtD
Everolimus—X-linked lymphoproliferative syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.0367	CcSEcCtD
Everolimus—Wound—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.0343	CcSEcCtD
Everolimus—Haemolytic uraemic syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.0228	CcSEcCtD
Everolimus—Acute respiratory distress syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.019	CcSEcCtD
Everolimus—Thrombotic thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000987	0.0174	CcSEcCtD
Everolimus—Nephrotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.000887	0.0156	CcSEcCtD
Everolimus—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.000807	0.0142	CcSEcCtD
Everolimus—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.000807	0.0142	CcSEcCtD
Everolimus—Renal tubular necrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00079	0.0139	CcSEcCtD
Everolimus—Pyelonephritis—Cyclosporine—focal segmental glomerulosclerosis	0.000742	0.0131	CcSEcCtD
Everolimus—Hypertrichosis—Cyclosporine—focal segmental glomerulosclerosis	0.000742	0.0131	CcSEcCtD
Everolimus—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.000611	0.0108	CcSEcCtD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—EDN1—focal segmental glomerulosclerosis	0.000601	0.0758	CbGpPWpGaD
Everolimus—Azotaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000529	0.00933	CcSEcCtD
Everolimus—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.000523	0.00921	CcSEcCtD
Everolimus—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.000497	0.00876	CcSEcCtD
Everolimus—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000491	0.00865	CcSEcCtD
Everolimus—Nephropathy toxic—Cyclosporine—focal segmental glomerulosclerosis	0.000491	0.00865	CcSEcCtD
Everolimus—Hirsutism—Cyclosporine—focal segmental glomerulosclerosis	0.000485	0.00855	CcSEcCtD
Everolimus—MTOR—IFN-gamma pathway—PIAS1—focal segmental glomerulosclerosis	0.000464	0.0586	CbGpPWpGaD
Everolimus—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000459	0.00808	CcSEcCtD
Everolimus—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.000449	0.00791	CcSEcCtD
Everolimus—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000444	0.00782	CcSEcCtD
Everolimus—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000435	0.00766	CcSEcCtD
Everolimus—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.000431	0.00759	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—focal segmental glomerulosclerosis	0.000414	0.0522	CbGpPWpGaD
Everolimus—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.000399	0.00702	CcSEcCtD
Everolimus—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.000399	0.00702	CcSEcCtD
Everolimus—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000391	0.0069	CcSEcCtD
Everolimus—MTOR—Interferon type I signaling pathways—PIAS1—focal segmental glomerulosclerosis	0.000387	0.0488	CbGpPWpGaD
Everolimus—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.000375	0.0066	CcSEcCtD
Everolimus—FKBP1A—TGF-beta receptor signaling—CTGF—focal segmental glomerulosclerosis	0.000367	0.0463	CbGpPWpGaD
Everolimus—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.000365	0.00644	CcSEcCtD
Everolimus—Coagulopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000362	0.00638	CcSEcCtD
Everolimus—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000359	0.00633	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—COL4A1—focal segmental glomerulosclerosis	0.000338	0.0427	CbGpPWpGaD
Everolimus—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00591	CcSEcCtD
Everolimus—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000321	0.00566	CcSEcCtD
Everolimus—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.000319	0.00562	CcSEcCtD
Everolimus—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.000312	0.0055	CcSEcCtD
Everolimus—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00031	0.00547	CcSEcCtD
Everolimus—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00031	0.00547	CcSEcCtD
Everolimus—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.000306	0.00539	CcSEcCtD
Everolimus—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000304	0.00536	CcSEcCtD
Everolimus—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.000302	0.00532	CcSEcCtD
Everolimus—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000296	0.00522	CcSEcCtD
Everolimus—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.000296	0.00522	CcSEcCtD
Everolimus—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.000287	0.00506	CcSEcCtD
Everolimus—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.000282	0.00497	CcSEcCtD
Everolimus—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000277	0.00488	CcSEcCtD
Everolimus—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—focal segmental glomerulosclerosis	0.000272	0.0342	CbGpPWpGaD
Everolimus—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.000269	0.00475	CcSEcCtD
Everolimus—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.000268	0.00472	CcSEcCtD
Everolimus—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.000266	0.00469	CcSEcCtD
Everolimus—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00449	CcSEcCtD
Everolimus—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00449	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00025	0.0316	CbGpPWpGaD
Everolimus—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000245	0.00431	CcSEcCtD
Everolimus—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.00423	CcSEcCtD
Everolimus—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000235	0.00415	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—SPP1—focal segmental glomerulosclerosis	0.000234	0.0295	CbGpPWpGaD
Everolimus—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.000233	0.00411	CcSEcCtD
Everolimus—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000231	0.00407	CcSEcCtD
Everolimus—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000228	0.00401	CcSEcCtD
Everolimus—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.000219	0.00386	CcSEcCtD
Everolimus—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.000217	0.00382	CcSEcCtD
Everolimus—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000215	0.00379	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—WT1—focal segmental glomerulosclerosis	0.000212	0.0268	CbGpPWpGaD
Everolimus—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00021	0.0037	CcSEcCtD
Everolimus—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00021	0.0037	CcSEcCtD
Everolimus—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.000209	0.00368	CcSEcCtD
Everolimus—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.000202	0.00355	CcSEcCtD
Everolimus—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000192	0.00338	CcSEcCtD
Everolimus—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000188	0.00331	CcSEcCtD
Everolimus—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000187	0.0033	CcSEcCtD
Everolimus—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000185	0.00326	CcSEcCtD
Everolimus—FKBP1A—ALK1 signaling events—TGFB1—focal segmental glomerulosclerosis	0.000184	0.0232	CbGpPWpGaD
Everolimus—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000181	0.00319	CcSEcCtD
Everolimus—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000181	0.00318	CcSEcCtD
Everolimus—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000178	0.00314	CcSEcCtD
Everolimus—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000177	0.00312	CcSEcCtD
Everolimus—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.000174	0.00307	CcSEcCtD
Everolimus—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000174	0.00306	CcSEcCtD
Everolimus—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00017	0.003	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00017	0.0214	CbGpPWpGaD
Everolimus—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.000166	0.00292	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000165	0.0209	CbGpPWpGaD
Everolimus—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000164	0.0029	CcSEcCtD
Everolimus—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000164	0.00288	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—SERPINE1—focal segmental glomerulosclerosis	0.000163	0.0205	CbGpPWpGaD
Everolimus—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00016	0.00282	CcSEcCtD
Everolimus—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00016	0.00281	CcSEcCtD
Everolimus—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000159	0.0028	CcSEcCtD
Everolimus—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000158	0.00278	CcSEcCtD
Everolimus—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000158	0.00278	CcSEcCtD
Everolimus—MTOR—TSH signaling pathway—GNAQ—focal segmental glomerulosclerosis	0.000157	0.0198	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—focal segmental glomerulosclerosis	0.000156	0.0197	CbGpPWpGaD
Everolimus—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000156	0.00274	CcSEcCtD
Everolimus—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000155	0.00273	CcSEcCtD
Everolimus—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000155	0.00273	CcSEcCtD
Everolimus—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00271	CcSEcCtD
Everolimus—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00271	CcSEcCtD
Everolimus—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000153	0.0027	CcSEcCtD
Everolimus—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000153	0.0027	CcSEcCtD
Everolimus—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00015	0.00265	CcSEcCtD
Everolimus—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000149	0.00263	CcSEcCtD
Everolimus—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000149	0.00262	CcSEcCtD
Everolimus—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000148	0.00261	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—COL4A4—focal segmental glomerulosclerosis	0.000146	0.0185	CbGpPWpGaD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GNAQ—focal segmental glomerulosclerosis	0.000146	0.0184	CbGpPWpGaD
Everolimus—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.00251	CcSEcCtD
Everolimus—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.0025	CcSEcCtD
Everolimus—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.0025	CcSEcCtD
Everolimus—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.0025	CcSEcCtD
Everolimus—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000141	0.00248	CcSEcCtD
Everolimus—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000141	0.00248	CcSEcCtD
Everolimus—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.00246	CcSEcCtD
Everolimus—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000139	0.00245	CcSEcCtD
Everolimus—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000139	0.00245	CcSEcCtD
Everolimus—Tacrolimus—ALB—focal segmental glomerulosclerosis	0.000138	1	CrCbGaD
Everolimus—MTOR—Signaling by PDGF—COL4A1—focal segmental glomerulosclerosis	0.000135	0.017	CbGpPWpGaD
Everolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000132	0.0167	CbGpPWpGaD
Everolimus—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000131	0.00232	CcSEcCtD
Everolimus—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000129	0.00226	CcSEcCtD
Everolimus—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.00225	CcSEcCtD
Everolimus—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000127	0.00224	CcSEcCtD
Everolimus—MTOR—IL4-mediated signaling events—CD40LG—focal segmental glomerulosclerosis	0.000127	0.016	CbGpPWpGaD
Everolimus—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000125	0.00221	CcSEcCtD
Everolimus—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.00219	CcSEcCtD
Everolimus—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000123	0.00217	CcSEcCtD
Everolimus—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000122	0.00214	CcSEcCtD
Everolimus—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000121	0.00213	CcSEcCtD
Everolimus—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000119	0.00209	CcSEcCtD
Everolimus—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00205	CcSEcCtD
Everolimus—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00204	CcSEcCtD
Everolimus—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000114	0.00202	CcSEcCtD
Everolimus—MTOR—SREBP signalling—LPL—focal segmental glomerulosclerosis	0.000114	0.0144	CbGpPWpGaD
Everolimus—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000114	0.00201	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—COL4A3—focal segmental glomerulosclerosis	0.000114	0.0143	CbGpPWpGaD
Everolimus—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000113	0.002	CcSEcCtD
Everolimus—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000113	0.00199	CcSEcCtD
Everolimus—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000111	0.00196	CcSEcCtD
Everolimus—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00011	0.00194	CcSEcCtD
Everolimus—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000108	0.0019	CcSEcCtD
Everolimus—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000107	0.00188	CcSEcCtD
Everolimus—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000106	0.00188	CcSEcCtD
Everolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—focal segmental glomerulosclerosis	0.000106	0.0133	CbGpPWpGaD
Everolimus—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000105	0.00185	CcSEcCtD
Everolimus—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000105	0.00185	CcSEcCtD
Everolimus—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000105	0.00185	CcSEcCtD
Everolimus—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000105	0.00184	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000104	0.00184	CcSEcCtD
Everolimus—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000104	0.00183	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	0.000103	0.013	CbGpPWpGaD
Everolimus—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000103	0.00181	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—focal segmental glomerulosclerosis	0.000103	0.0129	CbGpPWpGaD
Everolimus—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000101	0.00177	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.000101	0.0127	CbGpPWpGaD
Everolimus—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.0001	0.00176	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—NOS2—focal segmental glomerulosclerosis	9.98e-05	0.0126	CbGpPWpGaD
Everolimus—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	9.87e-05	0.00174	CcSEcCtD
Everolimus—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	9.85e-05	0.00174	CcSEcCtD
Everolimus—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	9.78e-05	0.00172	CcSEcCtD
Everolimus—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	9.73e-05	0.00171	CcSEcCtD
Everolimus—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	9.59e-05	0.00169	CcSEcCtD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—focal segmental glomerulosclerosis	9.24e-05	0.0116	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	9.17e-05	0.00162	CcSEcCtD
Everolimus—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	9.1e-05	0.0016	CcSEcCtD
Everolimus—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	9.04e-05	0.00159	CcSEcCtD
Everolimus—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	8.97e-05	0.00158	CcSEcCtD
Everolimus—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	8.95e-05	0.00158	CcSEcCtD
Everolimus—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	8.86e-05	0.00156	CcSEcCtD
Everolimus—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	8.75e-05	0.00154	CcSEcCtD
Everolimus—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	8.69e-05	0.00153	CcSEcCtD
Everolimus—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	8.68e-05	0.00153	CcSEcCtD
Everolimus—Pain—Cyclosporine—focal segmental glomerulosclerosis	8.61e-05	0.00152	CcSEcCtD
Everolimus—Constipation—Cyclosporine—focal segmental glomerulosclerosis	8.61e-05	0.00152	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	8.36e-05	0.0105	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	8.35e-05	0.0105	CbGpPWpGaD
Everolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—focal segmental glomerulosclerosis	8.34e-05	0.0105	CbGpPWpGaD
Everolimus—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	8.29e-05	0.00146	CcSEcCtD
Everolimus—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	8.23e-05	0.00145	CcSEcCtD
Everolimus—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	7.96e-05	0.0014	CcSEcCtD
Everolimus—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	7.96e-05	0.0014	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	7.88e-05	0.00994	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	7.59e-05	0.00957	CbGpPWpGaD
Everolimus—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	7.42e-05	0.00131	CcSEcCtD
Everolimus—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	7.22e-05	0.00127	CcSEcCtD
Everolimus—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	7.12e-05	0.00125	CcSEcCtD
Everolimus—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	6.89e-05	0.00121	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	6.66e-05	0.0084	CbGpPWpGaD
Everolimus—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	6.66e-05	0.00117	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	6.45e-05	0.00814	CbGpPWpGaD
Everolimus—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	6.4e-05	0.00113	CcSEcCtD
Everolimus—Rash—Cyclosporine—focal segmental glomerulosclerosis	6.35e-05	0.00112	CcSEcCtD
Everolimus—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	6.34e-05	0.00112	CcSEcCtD
Everolimus—Headache—Cyclosporine—focal segmental glomerulosclerosis	6.31e-05	0.00111	CcSEcCtD
Everolimus—MTOR—B Cell Activation—CD79A—focal segmental glomerulosclerosis	6.22e-05	0.00784	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	6.01e-05	0.00758	CbGpPWpGaD
Everolimus—Nausea—Cyclosporine—focal segmental glomerulosclerosis	5.98e-05	0.00105	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	5.69e-05	0.00717	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	5.49e-05	0.00693	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	5.37e-05	0.00677	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	5.36e-05	0.00677	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	4.98e-05	0.00628	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—MMP9—focal segmental glomerulosclerosis	4.92e-05	0.0062	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—TGFB1—focal segmental glomerulosclerosis	4.8e-05	0.00605	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MYH9—focal segmental glomerulosclerosis	4.31e-05	0.00543	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	4.05e-05	0.00511	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	3.89e-05	0.00491	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.73e-05	0.00471	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.58e-05	0.00451	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	3.39e-05	0.00428	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIAS1—focal segmental glomerulosclerosis	3.39e-05	0.00427	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	3.25e-05	0.0041	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.02e-05	0.00381	CbGpPWpGaD
Everolimus—MTOR—Immune System—MYH9—focal segmental glomerulosclerosis	2.51e-05	0.00317	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	2.51e-05	0.00316	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.22e-05	0.00281	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.21e-05	0.00279	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	2.19e-05	0.00276	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	2.04e-05	0.00258	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.01e-05	0.00254	CbGpPWpGaD
Everolimus—FKBP1A—Disease—LPL—focal segmental glomerulosclerosis	2e-05	0.00252	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.86e-05	0.00234	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	1.7e-05	0.00215	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.7e-05	0.00214	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—focal segmental glomerulosclerosis	1.56e-05	0.00197	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD79A—focal segmental glomerulosclerosis	1.52e-05	0.00192	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.44e-05	0.00182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.4e-05	0.00176	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.32e-05	0.00167	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—focal segmental glomerulosclerosis	1.31e-05	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.25e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.24e-05	0.00157	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—focal segmental glomerulosclerosis	1.24e-05	0.00156	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.2e-05	0.00151	CbGpPWpGaD
Everolimus—MTOR—Disease—LPL—focal segmental glomerulosclerosis	1.12e-05	0.00142	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.11e-05	0.00139	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.05e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.56e-06	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.2e-06	0.00116	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—focal segmental glomerulosclerosis	8.77e-06	0.00111	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—focal segmental glomerulosclerosis	8.29e-06	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	8.11e-06	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.87e-06	0.000992	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.45e-06	0.00094	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—focal segmental glomerulosclerosis	7.39e-06	0.000932	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.05e-06	0.000889	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.73e-06	0.000849	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.22e-06	0.000784	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.81e-06	0.000733	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.17e-06	0.000653	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—focal segmental glomerulosclerosis	4.66e-06	0.000588	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	4.09e-06	0.000516	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.96e-06	0.0005	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	3.6e-06	0.000454	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.32e-06	0.000418	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.27e-06	0.000412	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.5e-06	0.000315	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.13e-06	0.000269	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.64e-06	0.000207	CbGpPWpGaD
